Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats

European Journal of Pharmacology

Volumn 594, Issue 1-3, 2008, Pages 101-108

  Capitelli, Caroline ^a   Sereniki, Adriana ^a   Lima, Marcelo Meira Santos ^a,b   Reksidler, Angela Braga ^a   Tufik, Sergio ^b   Vital, Maria Aparecida Barbato Frazão ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Active avoidance; Cognitive impairment; Melatonin; MPTP; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MELATONIN; NEUROTOXIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; AVOIDANCE LEARNING; DOPAMINE; IMMUNOHISTOCHEMISTRY; MALE; MELATONIN; MOTOR ACTIVITY; MPTP POISONING; NEURONS; RATS; RATS, WISTAR; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 50549091192     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.022     Document Type: Article

References (62)

1. Akkas S.B., Inci S., Zorlu F., and Severcan F. Melatonin affects the order, dynamics and hydration of brain membrane lipids. J. Mol. Struct. 384-386 (2007) 207-215
2. Alam Z.I., Jenner A., Daniel E., Lees A.J., Cairns N., Marsden D., Jenner P., and Halliwell B. Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69 (1997) 1196-1203
3. Barlow-Walden L.R., Reiter R.J., Abe M., Pablos M., Menendez-Pelaez A., Chen L.-D., and Poeggeler B. Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int. 26 (1995) 497-502
4. Baydas G., Ferit Gursu M., Yilmaz S., Canpolat S., Yasar A., Cikim G., and Canatan H. Daily rhythm of glutathione peroxidase activity, lipid peroxidation and glutathione levels in tissues of pinealectomized rats. Neurosci. Lett. 323 (2002) 195-198
5. Baydas G., Ozveren F., Akdemir I., Tuzcu M., and Yasar A. Learning and memory deficits in rats induced by chronic thinner exposure are reversed by melatonin. J. Pineal Res. 39 (2005) 50-56
6. Cardinali D.P., and Pévet P. Basic aspects of melatonin action. Sleep Méd. Rev. 2 (1998) 175-190
7. Chen S.T., and Chuang J.I. The antioxidant melatonin prevents kainate-induced neuronal degenerating death in the rat striatum. Exp. Brain Res. 124 (1999) 241-247
8. Chen S.T., Chuan J.I., Hong M.H., and I-Chian E. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J. Pineal. Res. 32 (2002) 262-269
9. Chen C., Yin M., Hsu C., and Liu T. Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition 23 (2007) 589-597
10. Chetsawang B., Govitrapong P., and Ebadi M. The neuroprotective effect of melatonin against the induction of c-Jun phosphorylation by 6-hydroxydopamine on SK-N-SH cells. Neurosci. Lett. 371 (2004) 205-208
11. Cho S., Joh T.H., Baik H.H., Dibinis C., and Volpe B.T. Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res. 755 (1997) 335-338
12. Claustrat B., Brun J., and Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 9 (2005) 11-24
13. Cui K., Luo X., Xu K., and Vem Murthy M.R. Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 771-799
14. Da Cunha C., Gevaerd M.S., Vital M.A.B.F., Miyoshi E., Andreatini R., Silveira R., Takahashi R.N., and Canteras N.S. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav. Brain Res. 124 (2001) 9-18
15. Dauer W., and Przedborski S. Parkinson's disease: mechanism and models. Neuron 39 (2003) 889-909
16. DeMuro R.L., Nafziger A.N., Blask D.E., Menhinick A.M., and Bertino J.S. The absolute bioavailability of oral melatonin. Altern. Herbal Med. 40 (2000) 781-784
17. Di Filippo M., Picconi B., Costa C., Bagetta V., Parnetti L., and Calabrezi P. Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition (review). Eur. J. Pharmacol. 545 (2006) 65-72
18. Eybl V., Kotyzova D., and Koutensky J. Comparative study of natural antioxidants- curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Toxicol. 225 (2006) 150-156
19. Fredriksson A., and Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J. Neural Transm., Parkinson's Dis. Dement. Sect. 7 (1994) 123-132
20. Gao H., Liu B., Wangging Z., and Jau-Shyong H. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24 (2003) 395-400
21. Gaspar P., Fevret A., and Colombo J. Serotonergic sprouting in primate MPTP-induced hemiparkinsonism. Exp. Brain Res., 96 (1993) 100-106
22. German D.C., Nelson E.L., Liang C.L., Speciale S.G., Sinton C.M., and Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5 (1996) 299-312
23. Gevaerd M.S., Miyoshi E.S., Canteras N.S., Takahashi R.N., and Da Cunha C. L-DOPA restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int. J. Neuropsychopharmacol. 4 (2001) 361-370
24. Hardeland R., Pandi-Perumal S.R., and Cardinali D.P. Melatonin. Int. J. Biochem. Cell Biol. 38 (2006) 313-316
25. Heikkila R.E., He ss A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
26. Heikkila R.E., and Sonsalla P.K. The MPTP-treated mouse as a model of parkinsonism: how good is it?. Neurochem. Int. (1992) 299S-303S Suppl
27. +) neurotoxicity in rats. Neurosci. Lett. 245 (1998) 61-64
28. Kawasaki T., Ishihara K., Ago Y., Baba A., and Matsuda T. Edaravone (3-Methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J. Pharmacol. Exp. Ther., 322 (2007) 274-281
29. Khaldy H., Escames G., Leon J., Bikjdaouene L., and Acunã-Castroviejo D. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol. Aging 24 (2003) 491-500
30. Kidd P.M. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern. Med. Rev. 5 (2000) 502-545
31. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res 318 (2004) 115-120
32. Lima M.M.S., Rekslider A.B., Zanata S.M., Machado H.B., Tufik S., and VITAL M.A.B.F. Different parkinsonism models produced time-dependent induction COX-2 in the substantia nigra of rats. Brain Res. 1101 (2006) 117-125
33. Lima M.M.S., Andersen M.L., Reksidler A.B., Vital M.A.B.F., and Tufik S. The role of the dopaminergic pathway in regulating sleep-wake patterns in a model of Parkinson's Disease in rats. Sleep Med. 8 (2007) S103
34. Mayo J.C., Sainz R.M., Uria H., Antolín I., Esteban M.M., and Rodriguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: Implications for Parkinson's disease. J. Pineal Res. 24 (1998) 179-192
35. Miyoshi E., Wietzikoski S., Camplessei M., Silveira R., Takahashi R.N., and Da Cunha C. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res. Bull. 58 (2002) 41-47
36. Nam E., Lee M.S., Koh S.E., Joo W.S., Maeng S., Im H.I., and Kim Y.S. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rats striatum. Brain Res. 1046 (2005) 90-96
37. Park S., Kim S., Park K., Kim S., Kim J., Baek Y., Chung B., and Kang C. Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci. Lett., 363 (2004) 243-246
38. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, San Diego
39. Pearce R.K., Owen A., Daniel S., Jenner P., and Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104 (1997) 661-667
40. Perry J.C., Da Cunha C., Anselmo-Franci J., Andreatini R., Miyoshi E., Tufik S., and Vital M.A.B.F. Behavioural and neurochemical effects phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur. J. Pharmacol. 484 (2004) 225-233
41. Perry J.C., Hipólide D.C., Tufik S., Martins R.D., DA Cunha C., Andreatini R., and Vital M.A.B.F. Intra-nigral MPTP lesion in rats: behavioural and autoradiography studies. Exp. Neurol. 195 (2005) 322-329
42. Reiter R.J. Oxidative damage in the central nervous system: protection by melatonin. Eur. J. Pharmacol. 56 (1998) 359-384
43. Reksidler A.B., Lima M.M.S., Zanata S.M., Machado H.D., Da Cunha C., Andreatini R., Tufik S., and Vital M.A.B.F. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur. J. Pharmacol. 560 (2007) 163-175
44. Reksidler A.B., Lima M.M.S., Dombroski P., Andersen M.L., Zanata S.M., Andreatini R., Tufik S., and Vital M.A.B.F. Repeated intranigral MPTP administration: A new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J. Neurosci. Methods 167 (2008) 268-277
45. Rodriguez C., Mayo J.C., Sainz R.M., Antolín I., He rrera F., Martin V., and Reiter R.J. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36 (2004) 1-9
46. Sanchez-Ramos J.R., Overvik E., and Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2'-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3 (1994) 197-204
47. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J. Pineal Res. 42 (2007) 247-253
48. Schneider J.S., and Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of Parkinsonism in the monkey. Neurodegeneration 4 (1995) 245-255
49. Schulz J.B., and Falkenburger B.H. Neuronal pathology in Parkinson's disease. Cell Tissue Res 318 (2004) 135-147
50. Sedelis M., Schwarting R.K.W., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
51. 2-induced lipid peroxidation in rat brain homogenates is greatly reduced by melatonin. Neurosc. Lett. 195 (1995) 203-205
52. Shapira A.H.V., Mann V.M., Cooper J.M., Krige D., Jenner P.J., and Marsden C.D. Mitochondrial function in Parkinson's disease. Ann. Neurol. 32 (1992) S116-S124
53. Sharma R., McMillan C.R., Tenn C.C., and Niles L.P. Physiology neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068 (2006) 230-236
54. Shimura-Miura H., Hattori N., Kang D., Miyako K., Nakabeppu Y., and Mizuno Y. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann. Neurol. 46 (1999) 920-924
55. Skene D.J., Timbers S.E., Middleton B., English J.K.C., Tobler I., and Ioannides C. Mice convert melatonin to 6-sulphatoxymelatonin. Gen. Comp. Endocrinol. 147 (2006) 371-376
56. Soto-Moyano R., Burgos H., Flores F., Valladares L., Sierralta W., Fermandez W., Perez H., Hernandez P., and Hernandez A. Melatonin administration impairs visuo-spatial performance and inhibits neocortical long-term potentiation in rats. Pharmacol. Biochem. Behav. 85 (2006) 408-414
57. Stull N.D., Polan D.P., and Iacovitti L. Antioxidant compounds protect dopamine neurons from death due to oxidative stress in vitro. Brain Res. 931 (2002) 181-185
58. Subramanian P., Mirunalini S., Pandi-Perumal S.R., Trakht I., and Cardinali D.P. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur. J. Pharmacol. 571 (2007) 116-119
59. Takahashi H., and Wakabayashi K. Controversy: is Parkinson's disease entity? Yes. Parkinsonism Relat. Disord. 11 (2005) S31-S37
60. Tan D., Manchester L.C., Terron M.P., Flores L.J., and Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 42 (2007) 28-42
61. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine. Exp. Neurol. 178 (2002) 80-90
62. Wang W., Shi L., Xie Y., Ma C., Li W., Su X., Huang S., Chen R., Zhu Z., Mao Z., Han Y., and Li M. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosc. Res. 48 (2004) 195-202